<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19077" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Toxicology, V-Series Nerve Agents</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hayoun</surname>
            <given-names>Michael A.</given-names>
          </name>
          <aff>Tristar Healthcare Network</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ausman</surname>
            <given-names>Chelsea</given-names>
          </name>
          <aff>Landstuhl Regional Medical Center DEM</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Yarrarapu</surname>
            <given-names>Siva Naga S.</given-names>
          </name>
          <aff>Monmouth Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Swoboda</surname>
            <given-names>Henry D.</given-names>
          </name>
          <aff>Rush Medical College</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michael Hayoun declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Chelsea Ausman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Siva Naga Yarrarapu declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Henry Swoboda declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19077.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>V-Series nerve agents are organophosphate esters that are used as chemical weapons. They are extremely potent acetylcholinesterase inhibitors. Biological effects include seizures, salivation, lacrimation, urination, diaphoresis, diarrhea, vomiting, miosis, and muscles spasms. As little as a few milligrams of some V-series agents can be lethal to humans. This activity reviews the pathophysiology, evaluation, and treatment of patients affected by V-series agents and highlights the role of the interprofessional team in caring for these patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the epidemiology of V-series nerve agents.</p></list-item><list-item><p>Describe the pathophysiology of V-series nerve agents.</p></list-item><list-item><p>Summarize the treatment of patients affected by V-series nerve agents.</p></list-item><list-item><p>Review the importance of improving care coordination amongst interprofessional team members in order to deliver care to patients affected by V-series nerve agents as well as the importance of communicating with health officials, law enforcement agencies, members of the media, and elected officials in the management of incidents involving V-series nerve agents.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19077&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19077">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19077.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>V-Series nerve agents are organophosphate esters that are used as chemical weapons. They are extremely potent acetylcholinesterase inhibitors. Biological effects include seizures, salivation, lacrimation, urination, diaphoresis, diarrhea, vomiting, miosis, and muscles spasms. As little as a few milligrams of some V-series agents can be lethal to humans.</p>
      </sec>
      <sec id="article-19077.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The V-series nerve agents were first discovered in 1952 by scientists in the United Kingdom researching organophosphate esters as pesticides.</p>
        <p>The five most well-known V-series nerve agents:</p>
        <list list-type="bullet">
          <list-item>
            <p>VX.&#x000a0; O-Ethyl-S-[2(diisopropylamino)ethyl] methylphosphonothioate</p>
          </list-item>
          <list-item>
            <p>VE.&#x000a0; O-Ethyl-S-[2-(diethylamino)ethyl] ethylphosphonothioate</p>
          </list-item>
          <list-item>
            <p>VG.&#x000a0; O,O-Diethyl-S-[2-(diethylamino)ethyl] phosphorothioate</p>
          </list-item>
          <list-item>
            <p>VM.&#x000a0; O-Ethyl-S-[2-(diethylamino)ethyl] methylphosphonothioate</p>
          </list-item>
          <list-item>
            <p>VR.&#x000a0; <italic toggle="yes">N</italic>-diethyl-2-(methyl-(2-methylpropoxy)phosphoryl)sulfanylethanamine</p>
          </list-item>
        </list>
        <p>VR is the compound from which Soviet newcomer agents (Novichok) Novichok 5 and Novichok 7, are derived. <xref ref-type="bibr" rid="article-19077.r1">[1]</xref></p>
        <p>V-series nerve agents are highly viscous and have low volatility; thus, they can persist in the environment and are difficult to wash away. They are oily liquids at room temperature. Some V-series agents can be deployed as binary agents, in which two non-toxic chemicals react together inside the weapon before deployment to form the chemical weapon. For example, isopropyl aminomethyl ethyl phosphorite and elemental sulfur react to form VX. V-series agents can be deployed as liquids or aerosols.</p>
      </sec>
      <sec id="article-19077.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Thousands of tons of V-series nerve agents were stockpiled during the 1950s and 1960s in the form of rockets, bombs, artillery shells, aerosol sprays, and landmines. Remnants of VX were detected on warheads used by Saddam Hussein against Iraqi Kurds in Halabja in 1988. The Japanese cult Aum Shinrikyo used VX to attack three people in 1994 and 1995, one of whom died. Stockpiles of V-series nerve agents continue to be disposed of following the 1997 Chemical Weapons Convention. The remaining VX in the United States will be destroyed at the Blue Grass Chemical Agent Destruction Pilot Plant near Richmond, Kentucky. Russian has developed a series of Novichok agents that are more potent than the first generation of V agents. They have been implicated in assassination attempts of Sergei Skripal and Alexei Navalny.</p>
      </sec>
      <sec id="article-19077.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>V-series nerve agents inhibit acetylcholinesterase. The phosphorus moeity binds to the phosphoryl group in the esteratic subsite. The role of the acetylcholinesterase enzyme is to break down acetylcholine in the synapse into acetate and choline, and the enzyme can degrade approximately 25,000 molecules of acetylcholine per second. When the acetylcholinesterase enzyme is inhibited, it causes acetylcholine to accumulate in the synapse and thus continue to stimulate the acetylcholine receptors. Salivation, lacrimation, urination, diarrhea, and vomiting are caused by the stimulation of muscarinic acetylcholine receptors in the parasympathetic nervous systems. Skeletal muscle symptoms of fasiculation and paralysis are caused by the stimulation of nicotinic acetylcholine receptors. Nerve agents have also demonstrated the ability to inhibit other enzymes, including neurotoxic esterase (NTE).&#x000a0;<xref ref-type="bibr" rid="article-19077.r2">[2]</xref><xref ref-type="bibr" rid="article-19077.r3">[3]</xref></p>
      </sec>
      <sec id="article-19077.s6" sec-type="Toxicokinetics">
        <title>Toxicokinetics</title>
        <p>The median lethal dose of VX for humans is approximately 6 to 10 milligrams by dermal exposure. Absorption is rapid (seconds to minutes) by inhalation but is significantly slower (minutes to hours) by dermal exposure. V-series nerve agents are odorless and tasteless. Biologic half-lives of V-series agents in humans are dependent on the dose administered as well as numerous other factors.&#x000a0;</p>
      </sec>
      <sec id="article-19077.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The only use of V-series nerve agents (other than for research) is a chemical weapon. Thus, patients exposed to these agents may present in large numbers and report a history consistent with a terrorist attack. Symptoms are identical to those of the organophosphate toxidrome and include seizures, salivation, rhinorrhea, lacrimation, urination, diaphoresis, diarrhea, vomiting, miosis, and muscles spasms. Other symptoms include bronchospasm, central apnea, and bradycardia. Most deaths occur because of respiratory failure from the combination of respiratory symptoms. Those who survive nerve agent exposure may experience insomnia, depression, anxiety, irritability, and impaired memory and judgment. Ocular symptoms such as miosis, dim vision, blurry vision, and eye pain may persist for several weeks following exposure. Long-term neurologic effects of nerve agents have been reported.<xref ref-type="bibr" rid="article-19077.r2">[2]</xref></p>
      </sec>
      <sec id="article-19077.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Exposure to V-series nerve agents should be considered if there is a clinical history concerning for exposure to nerve agents or symptoms of nerve agent exposure. Decontamination and treatment should begin as soon as possible. Laboratory tests for the presence of V-series agents in the body are not readily available and are not used to guide management. Patients may demonstrate lab abnormalities consistent with metabolic acidosis and the breakdown of striated muscle. Decreased erythrocyte cholinesterase levels may be observed after exposure to nerve agents. V-series nerve agents can also be detected in patients or in the environment by M8 paper, M9 tape, the M256A1 Chemical Agent Detector Kit, or the Joint Chemical Agent Detector (JCAD).&#x000a0;<xref ref-type="bibr" rid="article-19077.r4">[4]</xref><xref ref-type="bibr" rid="article-19077.r5">[5]</xref><xref ref-type="bibr" rid="article-19077.r6">[6]</xref><xref ref-type="bibr" rid="article-19077.r7">[7]</xref><xref ref-type="bibr" rid="article-19077.r8">[8]</xref><xref ref-type="bibr" rid="article-19077.r9">[9]</xref></p>
      </sec>
      <sec id="article-19077.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The most important treatment is to terminate the patient's exposure by removing them from the contaminated environment and performing decontamination. Decontamination of the patient should always be performed before further medical treatment if possible. Some nerve agents may remain in the skin and continue to cause symptoms via a depot effect. Patients can be decontaminated by washing the affected areas with a 0.5% hypochlorite solution or with soap and&#x000a0;clean water. However, the most effective method of decontamination of patients exposed to nerve agents is Reactive Skin Decontamination Lotion (RSDL), which should be used if available. The ingredients of&#x000a0;Reactive Skin Decontamination Lotion&#x000a0;sequester, retain, and neutralize organophosphate chemical warfare agents. Patients with large areas of dermal exposure will require numerous&#x000a0;Reactive Skin Decontamination Lotion&#x000a0;sponges to be effectively decontaminated.</p>
        <p>Patients known to have been exposed to nerve agents or those exhibiting symptoms of nerve agent exposure should be given the antidote medications atropine and pralidoxime. Atropine works by binding and blocking muscarinic acetylcholine receptors, thus preventing the buildup of acetylcholine from continuing to affect the receptors. Because atropine does not act on nicotinic receptors, it will not improve skeletal muscle symptoms. Atropine should be administered until there is clinically evident reduction of airway secretions and airway resistance; doses of atropine can be given every three to five minutes. When administered soon after exposure to nerve agents, pralidoxime (also known as 2-pyridine aldoxime methyl chloride or 2-PAM Cl) removes the phosphyl moiety from acetylcholinesterase, thus reactivating the enzyme. Dual-chamber auto-injectors have been developed containing atropine sulfate and pralidoxime; examples of these include the Mark I Nerve Agent Antidote Kit (NAAK) or the newer Antidote Treatment Nerve Agent Autoinjector (ATNAA). Each&#x000a0;Antidote Treatment Nerve Agent Autoinjector&#x000a0;contains 2.1 mg of atropine and 600mg of pralidoxime.</p>
        <p>Patients are also given diazepam or midazolam to prevent seizures and convulsions. When given intramuscularly, midazolam is absorbed faster than diazepam. The United States military uses a specialized&#x000a0;diazepam auto-injector called&#x000a0;the Convulsive Antidote Nerve Agent (CANA). Patients may be given up to three&#x000a0;Antidote Treatment Nerve Agent Autoinjector&#x000a0;autoinjectors. After three&#x000a0;Antidote Treatment Nerve Agent Autoinjectors have been given, patients may receive additional doses of atropine every three to five minutes as clinically indicated, however additional doses of pralidoxime should not be given for 60 to 90 minutes. Patients who receive three&#x000a0;Antidote Treatment Nerve Agent Autoinjector&#x000a0;autoinjectors should also receive a&#x000a0;Convulsive Antidote Nerve Agent&#x000a0;(or a dose of benzodiazepine) even if there is no visible evidence of seizures. Medication administration by autoinjector has been shown to cause plasma concentrations of these medications to each therapeutic levels faster than intramuscular administration using a needle and syringe. Scopolamine is effective at blocking the muscarinic effects of acetylcholine in the central nervous system, and low doses of scopolamine can significantly reduce the amount of atropine needed for a patient. Opiates, phenothiazines, antihistamines, and succinylcholine should be avoided in patients that have been exposed to V-series nerve agents.&#x000a0;<xref ref-type="bibr" rid="article-19077.r10">[10]</xref><xref ref-type="bibr" rid="article-19077.r11">[11]</xref><xref ref-type="bibr" rid="article-19077.r3">[3]</xref><xref ref-type="bibr" rid="article-19077.r12">[12]</xref><xref ref-type="bibr" rid="article-19077.r13">[13]</xref><xref ref-type="bibr" rid="article-19077.r14">[14]</xref></p>
      </sec>
      <sec id="article-19077.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>CBRNE - Chemical warfare agents</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>CBRNE &#x02013; Nerve agents, binary - GB2, VX2</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>CBRNE &#x02013; Nerve agents, G-series &#x02013; Tabun, Sarin, Soman</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Organic phosphorus compound and carbamate toxicity</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Organophosphate toxicity</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19077.s11" sec-type="Treatment Planning ">
        <title>Treatment Planning </title>
        <p>The U.S. has stockpiles of all 3 antidotes (Atropine, pralidoxime, and benzodiazepine) in the CHEMPACK program. There are pre-hospital CHEMPACKS and Hospital-based CHEMPACKs with slightly different amounts of antidotes in them. The must be kept in a climate control location and linked by secure phone connections to a central location that monitors whether they are opened.</p>
      </sec>
      <sec id="article-19077.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The V series are lethal agents. Immediately decontamination and administering antidotes as soon as suspected will improve the chances of survival.</p>
      </sec>
      <sec id="article-19077.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>Consultation with the regional Poison Control Center is extremely helpful in these cases, especially on guidance for repeating doses and duration of treatment.</p>
      </sec>
      <sec id="article-19077.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The assassination of Kim Jong-nam with VX in the Kuala Lumpur International Airport in February 2017 and the poisoning of Sergei and Yulia Skripal with a 'Novichok' (Russian for 'newcomer') nerve agent in the United Kingdom in March 2018 serve as examples of how nerve agent attacks with even one or two victims will quickly become international news. Once a patient has been diagnosed with a V-series nerve agent exposure, healthcare providers will be responsible for communicating not only numerous colleagues and staff but also with public health officials, law enforcement agencies, members of the media, and elected officials. The marshaling of resources to respond will almost certainly reach the national and international levels. (Level V)</p>
        <p>Important communication points early in the care of the patient among physicians, nurses, and pharmacists will include adequate decontamination of the patient and appropriate precautions for first responders and hospital staff to avoid additional casualties. Training and education prior to such an event will be more effective than just-in-time training after an event has occurred when emotions run high and resources may run low. In large-scale events, it will be essential for healthcare staff to have a clear understanding of their available resources, and continuously communicating with government officials to access medical supply stockpiles and&#x000a0;resources for&#x000a0;the capacity&#x000a0;to treat large numbers of patients will be vital. (Level V)</p>
      </sec>
      <sec id="article-19077.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19077&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19077">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/injury-safety-and-violence/toxicology-v-series-nerve-agents/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=19077">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19077/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19077">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-19077.s16">
        <title>References</title>
        <ref id="article-19077.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chai</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Erickson</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>EW</given-names>
              </name>
            </person-group>
            <article-title>Novichok agents: a historical, current, and toxicological perspective.</article-title>
            <source>Toxicol Commun</source>
            <year>2018</year>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-48</page-range>
            <pub-id pub-id-type="pmid">30003185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19077.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peter</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Sudarsan</surname>
                <given-names>TI</given-names>
              </name>
              <name>
                <surname>Moran</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Clinical features of organophosphate poisoning: A review of different classification systems and approaches.</article-title>
            <source>Indian J Crit Care Med</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>18</volume>
            <issue>11</issue>
            <fpage>735</fpage>
            <page-range>735-45</page-range>
            <pub-id pub-id-type="pmid">25425841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19077.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petroianu</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Organophosphate poisoning: the lesser-known face of a toxidrome.</article-title>
            <source>Eur J Emerg Med</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>102</fpage>
            <page-range>102-3</page-range>
            <pub-id pub-id-type="pmid">15756089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19077.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cone</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>MacMillan</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Parwani</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Van Gelder</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Pilot test of a proposed chemical/biological/radiation/ nuclear-capable mass casualty triage system.</article-title>
            <source>Prehosp Emerg Care</source>
            <year>2008</year>
            <season>Apr-Jun</season>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>236</fpage>
            <page-range>236-40</page-range>
            <pub-id pub-id-type="pmid">18379923</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19077.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joosen</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>van den Berg</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>de Jong</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>van der Schans</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Noort</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Langenberg</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>The impact of skin decontamination on the time window for effective treatment of percutaneous VX exposure.</article-title>
            <source>Chem Biol Interact</source>
            <year>2017</year>
            <month>Apr</month>
            <day>01</day>
            <volume>267</volume>
            <fpage>48</fpage>
            <page-range>48-56</page-range>
            <pub-id pub-id-type="pmid">26855350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19077.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pantazides</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Crow</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Blake</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>An enhanced butyrylcholinesterase method to measure organophosphorus nerve agent exposure in humans.</article-title>
            <source>Anal Bioanal Chem</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>406</volume>
            <issue>21</issue>
            <fpage>5187</fpage>
            <page-range>5187-94</page-range>
            <pub-id pub-id-type="pmid">24604326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19077.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wolf</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Schaer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Siegenthaler</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zenobi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Direct quantification of chemical warfare agents and related compounds at low ppt levels: comparing active capillary dielectric barrier discharge plasma ionization and secondary electrospray ionization mass spectrometry.</article-title>
            <source>Anal Chem</source>
            <year>2015</year>
            <month>Jan</month>
            <day>06</day>
            <volume>87</volume>
            <issue>1</issue>
            <fpage>723</fpage>
            <page-range>723-9</page-range>
            <pub-id pub-id-type="pmid">25427190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19077.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kycia</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Vezvaie</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zamlynny</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lipkowski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Petryk</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>Non-contact detection of chemical warfare simulant triethyl phosphate using PM-IRRAS.</article-title>
            <source>Anal Chim Acta</source>
            <year>2012</year>
            <month>Aug</month>
            <day>06</day>
            <volume>737</volume>
            <fpage>45</fpage>
            <page-range>45-54</page-range>
            <pub-id pub-id-type="pmid">22769035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19077.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacquet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Daud&#x000e9;</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bzdrenga</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Masson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Elias</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chabri&#x000e8;re</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Current and emerging strategies for organophosphate decontamination: special focus on hyperstable enzymes.</article-title>
            <source>Environ Sci Pollut Res Int</source>
            <year>2016</year>
            <month>May</month>
            <volume>23</volume>
            <issue>9</issue>
            <fpage>8200</fpage>
            <page-range>8200-18</page-range>
            <pub-id pub-id-type="pmid">26832878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19077.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iyer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Iken</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Leon</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Developments in alternative treatments for organophosphate poisoning.</article-title>
            <source>Toxicol Lett</source>
            <year>2015</year>
            <month>Mar</month>
            <day>04</day>
            <volume>233</volume>
            <issue>2</issue>
            <fpage>200</fpage>
            <page-range>200-6</page-range>
            <pub-id pub-id-type="pmid">25595305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19077.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krivoy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rotman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Layish</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Horvitz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yehezkelli</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>[Medical management in the chemical terrorism scene].</article-title>
            <source>Harefuah</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>144</volume>
            <issue>4</issue>
            <fpage>266</fpage>
            <page-range>266-71, 302</page-range>
            <pub-id pub-id-type="pmid">15889611</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19077.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feeney</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ziegler</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Terrorist Event Training in US Medical Schools. A Survey of Chemical, Biologic, Radiologic, Nuclear, and High-Yield Explosives Training in US Medical Schools.</article-title>
            <source>Conn Med</source>
            <year>2015</year>
            <season>Nov-Dec</season>
            <volume>79</volume>
            <issue>10</issue>
            <fpage>581</fpage>
            <page-range>581-5</page-range>
            <pub-id pub-id-type="pmid">26731877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19077.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <collab>DISASTER PREPAREDNESS ADVISORY COUNCIL</collab>
            <article-title>Medical Countermeasures for Children in Public Health Emergencies, Disasters, or Terrorism.</article-title>
            <source>Pediatrics</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>137</volume>
            <issue>2</issue>
            <fpage>e20154273</fpage>
            <pub-id pub-id-type="pmid">26729737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19077.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>HX</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>Clinical study of continuous micropump infusion of atropine and pralidoxime chloride for treatment of severe acute organophosphorus insecticide poisoning.</article-title>
            <source>J Chin Med Assoc</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>78</volume>
            <issue>12</issue>
            <fpage>709</fpage>
            <page-range>709-13</page-range>
            <pub-id pub-id-type="pmid">26441220</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
